Opendata, web and dolomites

PoC-Cycle

Innovative Molecular Diagnostics point-of-care device for MRSA

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PoC-Cycle project word cloud

Explore the words cloud of the PoC-Cycle project. It provides you a very rough idea of what is the project "PoC-Cycle" about.

accuracy    health    detection    infections    semiconductor    sensitive    nucleic    cycle    approx    turnover    pathogens    2015    platform    version    safe    freedom    rapid    missing    few    operate    usability    17    business    complexity    pcr    multiplexing    reg    innovative    poc    sensitivity    revised    negative    ing    forecast    variations    reduce    workflow    area    patients    million    mostly    900    handling    almost    tuberculosis    biomarkers    experts    administration    pilot    microarrays    significantly    yearly    diagnosis    market    microfluidic    acid    prepares    optimized    tests    multiplex    deaths    sequence    friz    spread    validation    fast    introducing    appropriate    technically    limited    hospitals    hpv    feasibility    platforms    mrsa    collection    pathogen    combination    screening    routine    provides    interviewing    diagnostic    broad    acceptance    care    point    cartridge    format    discuss    diagnose    signatures    checked    robustness    diagnostics    disposable    multicentric    efficient    device   

Project "PoC-Cycle" data sheet

The following table provides information about the project.

Coordinator
FRIZ BIOCHEM GMBH 

Organization address
address: FLORIANSBOGEN 2-4
city: NEURIED
postcode: 82061
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.frizbiochem.de
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-09-01   to  2014-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FRIZ BIOCHEM GMBH DE (NEURIED) coordinator 50˙000.00

Map

 Project objective

FRIZ has developed PoC-Cycle® platform- an innovative diagnostics device introducing efficient multiplex nucleic acid testing to the point-of-care. It provides a combination of accuracy and sensitivity, multiplexing, and optimized workflow from sample collection to diagnosis. Current diagnostics platforms are technically limited: On one side only few sequence signatures can be checked, on the other side, the analysis of these signatures are mostly considered in one sequence area only due to the high complexity in developing Multiplex-PCR, as well as missing process-robustness for routine administration. FRIZ implemented a multiplex analysis in disposable microfluidic cartridge format with integrated semiconductor based on microarrays for the rapid and sensitive detection of a broad range and number of biomarkers. Key market is the screening of MRSA, a pathogen with wide spread and growing negative impact to European patients and health care systems. Experts forecast the number of deaths will increase from 6,000 to approx. 17,000 in 2015. Main users of the device are hospitals as they require simple and safe handling as well as fast and reliable results. European market potential can be estimated with 900,000 tests per year resulting in a yearly turnover of almost two million €. The new diagnostic device will significantly reduce the number of infections. Moreover, it provides future business opportunities due to its general approach for diagnose further pathogens e.g. HPV or tuberculosis. Within the project, FRIZ aims to identify end-users for validation, discuss the handling and identify possible variations to enhance the usability and acceptance of the new system in phase 2. To find an appropriate partner for validation is also part of this feasibility study. In addition, FRIZ prepares a revised version of a “freedom-to-operate” analysis. A multicentric validation study is planned as well as interviewing end-users and built up a pilot production in phase 2.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "POC-CYCLE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "POC-CYCLE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

PD_Pal (2019)

Palliative care in Parkinson’s disease

Read More